Engineering mRNA Vaccines for Solid Tumors: Challenges in Delivery, Stability, and Clinical Translation

Authors

  • Niranjan Giri MASTER OF PHARMACY
  • Umesh maske

Keywords:

mRNA cancer vaccine, Lipid nanoparticles, Tumor immunotherapy, Neoantigen, Endosomal escape

Abstract

Solid tumors remain a leading cause of cancer death despite advances in surgery,
chemotherapy, radiotherapy and immunotherapy. Messenger RNA (mRNA) vaccine
technology, validated at scale by the coronavirus disease 2019 (COVID-19) vaccines
BNT162b2 and mRNA-1273, offers rapid design, personalization, transient antigen
expression and induction of T-cell responses. Applying this platform to solid tumors,
however, raises engineering problems that differ from those of infectious-disease
vaccines. This review examines three of them: delivery, formulation stability and
clinical translation. We discuss lipid nanoparticles (LNPs), polymer-based carriers
and hybrid systems, together with sequence and nucleoside engineering and
strategies for improving stability and storage. Endosomal escape is a major delivery
bottleneck. In studies of LNPs loaded with small interfering RNA (siRNA), only about
1–2% of internalized cargo was found to reach the cytosol in the cell models
examined; the corresponding figure for mRNA depends on the formulation, cell type
and measurement method and should not be taken as a universal value. Nucleoside
modification, notably with N1-methylpseudouridine (m1Ψ), reduces innate immune
sensing of in vitro-transcribed mRNA and increases translation, but it does not abolish
immune activation, and removal of double-stranded RNA by-products remains
important. Clinically, in the phase 2b KEYNOTE-942 trial, adjuvant mRNA-4157
(V940) plus pembrolizumab reduced the risk of recurrence or death by 44% relative
to pembrolizumab alone (hazard ratio 0.56 for recurrence-free survival). This is a
relative risk reduction in a small, open-label, hypothesis-generating study; it is not a
demonstrated improvement in overall survival. Topline phase 3 results announced in
August 2026 await full publication, and, to our knowledge, no mRNA cancer vaccine
had received regulatory approval at the time of writing. Remaining hurdles include
mRNA instability, cold-chain requirements, tumor heterogeneity and
immunosuppressive tumor microenvironments.

Author Biography

  • Umesh maske

    Master of Pharmacy, Department of Pharmaceutics, Mangaldeep Institute of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

[2] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012

[3] Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x

[4] Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17-35. doi:10.1016/j.immuni.2019.12.011

[5] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi:10.1038/nrd.2017.243

[6] Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics - developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-780. doi:10.1038/nrd4278

[7] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577

[8] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

[9] Weng Y, Li C, Yang T, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534. doi:10.1016/j.biotechadv.2020.107534

[10] Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009-4017. doi:10.1182/blood-2006-04-015024

[11] Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991;5(11):2108-2116. doi:10.1101/gad.5.11.2108

[12] Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. doi:10.1186/s12943-021-01335-5

[13] Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23(8):526-543. doi:10.1038/s41568-023-00586-2

[14] Beissert T, Perkovic M, Vogel A, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 2020;28(1):119-128. doi:10.1016/j.ymthe.2019.09.009

[15] Palmer CD, Rappaport AR, Davis MJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619-1629. doi:10.1038/s41591-022-01937-6

[16] Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629. doi:10.1038/s41467-018-05096-6

[17] Iavarone C, O'Hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871-881. doi:10.1080/14760584.2017.1355245

[18] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059

[19] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951. doi:10.1038/nbt.3330

[20] Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. doi:10.1038/natrevmats.2016.14

[21] Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222-226. doi:10.1038/nature23003

[22] Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355-1360. doi:10.1126/science.aar7112

[23] Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692-696. doi:10.1038/nature14426

[24] Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144-150. doi:10.1038/s41586-023-06063-y

[25] Mauger DM, Cabral BJ, Presnyak V, et al. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A. 2019;116(48):24075-24083. doi:10.1073/pnas.1908052116

[26] Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165-175. doi:10.1016/j.immuni.2005.06.008

[27] Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833-1840. doi:10.1038/mt.2008.200

[28] Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38(17):5884-5892. doi:10.1093/nar/gkq347

[29] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi:10.1038/s41578-021-00358-0

[30] Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337-344. doi:10.1016/j.jconrel.2015.08.051

[31] Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 2017;45(10):6023-6036. doi:10.1093/nar/gkx135

[32] Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. doi:10.1093/nar/gkr695

[33] Nelson J, Sorensen EW, Mintri S, et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv. 2020;6(26):eaaz6893. doi:10.1126/sciadv.aaz6893

[34] Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251-259. doi:10.1038/mt.2012.202

[35] Beck JD, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20(1):69. doi:10.1186/s12943-021-01348-0

[36] Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710-728. doi:10.1016/j.ymthe.2019.02.012

[37] Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084-1087. doi:10.1038/s41565-019-0591-y

[38] Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153

[39] Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154-155:37-63. doi:10.1016/j.addr.2020.06.002

[40] Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172-176. doi:10.1038/nbt.1602

[41] Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529-8533. doi:10.1002/anie.201203263

[42] Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1-11. doi:10.1016/j.omtn.2019.01.013

[43] Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313-320. doi:10.1038/s41565-020-0669-6

[44] Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265-280. doi:10.1038/s41576-021-00439-4

[45] Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9(1):60. doi:10.1186/s13073-017-0450-0

[46] Tros de Ilarduya C, Sun Y, Düzgüneş N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159-170. doi:10.1016/j.ejps.2010.03.019

[47] Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396-401. doi:10.1038/nature18300

[48] Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107-112. doi:10.1038/s41586-020-2537-9

[49] Islam MA, Xu Y, Tao W, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018;2(11):850-864. doi:10.1038/s41551-018-0284-0

[50] Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804. doi:10.1126/scitranslmed.abc7804

[51] Papachristofilou A, Hipp MM, Klinkhardt U, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2022;10(6):e003945. doi:10.1136/jitc-2021-003945

[52] Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638-646. doi:10.1038/nbt.2612

[53] Sahay G, Querbes W, Alabi C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31(7):653-658. doi:10.1038/nbt.2614

[54] Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110(3):997-1001. doi:10.1016/j.xphs.2020.12.006

[55] Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun. 2021;12:6777. doi:10.1038/s41467-021-26926-0

[56] Zeng C, Zhang C, Walker PG, Dong Y. Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol. 2022;440:71-110. doi:10.1007/822020217

[57] Muramatsu H, Lam K, Bajusz C, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941-1951. doi:10.1016/j.ymthe.2022.02.001

[58] Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222-229. doi:10.1038/nbt.3802

[59] Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632-644. doi:10.1016/S0140-6736(23)02268-7

[60] Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577-581. doi:10.1038/nature13988

[61] Merck, Moderna. Merck and Moderna announce Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met endpoints of recurrence-free survival and distant metastasis-free survival in patients with resected melanoma. Press release. August 19, 2026.

[62] Novel cancer vaccine meets primary and secondary end points in resected melanoma. Cancer Network. August 19, 2026. https://www.cancernetwork.com/view/novel-cancer-vaccine-meets-primary-secondary-end-points-in-resected-melanoma

[63] Add-on mRNA cancer vaccine delivers promise for melanoma. MIMS Hong Kong. 2023. https://www.mims.com/hongkong/news-updates/topic/add-on-mrna-cancer-vaccine-delivers-promise-for-melanoma

[64] Ascierto PA, Grabbe S, Guida M, et al. Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma (BNT111-01, NCT04526899). Abstract 1605MO. Presented at: ESMO Congress 2025; October 17-21, 2025; Berlin, Germany.

[65] Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97-111. doi:10.1038/nri.2016.107

[66] Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019;7(2):37. doi:10.3390/vaccines7020037

[67] Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-221. doi:10.1038/nature22991

[68] Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449-W454. doi:10.1093/nar/gkaa379

[69] Maier MA, Jayaraman M, Matsuda S, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570-1578. doi:10.1038/mt.2013.103

Downloads

Published

2026-11-07

Issue

Section

Review articles